NutriDex

The Supplement Research Compendium
🩸

Erythritol

E968 · sugar alcohol

Zero-calorie sugar alcohol under fresh cardiovascular scrutiny

Mixed evidence 🍬Sweeteners & Additives

✚ Updated · How we grade evidence

Evidence tier
Mixed
Research weight
Citations
11 verified / 11
Classification
Sweeteners & Additives
❝
What the evidence says. Conflicting results across studies; benefit uncertain.

What is Erythritol?

Erythritol (E968 · sugar alcohol) is a sweetener or food additive used for zero/near-zero calorie sweetness (0-0.2 kcal/g, ~60-70% as sweet as sugar). NutriDex grades the human evidence as Mixed. Erythritol (E968) is a four-carbon sugar alcohol (polyol) used as a bulk, zero-calorie sweetener with about 60-70% the sweetness of sucrose. It is FDA GRAS (since 2001) and was given a JECFA ADI of "not specified" (2000); in a 2023 re-evaluation EFSA set an ADI of 0.5 g/kg body weight/day based solely on its laxative threshold. Unlike most polyols it is ~90% absorbed in the small intestine, not metabolized, and excreted unchanged in urine, giving it minimal glycemic, insulin, and GI impact at moderate doses. The weight of human evidence is reassuring for short-term metabolic safety but is now mixed because recent observational and mechanistic studies (Witkowski 2023-2024) link elevated circulating erythritol and acute ingestion to enhanced platelet reactivity and incident cardiovascular events — an unconfirmed signal under active study, complicated by the fact that erythritol is also produced endogenously.

Purported Benefits

✓Zero/near-zero calorie sweetness (0-0.2 kcal/g, ~60-70% as sweet as sugar)
✓No meaningful glycemic or insulin impact (glycemic index ~0) — suitable for diabetics and keto/low-carb diets
✓~90% absorbed in small intestine and excreted unchanged, so far better GI tolerance than other polyols (sorbitol, maltitol)
✓Non-cariogenic — not fermented by oral bacteria, does not promote tooth decay
✓Bulking agent that provides sugar-like texture and mouthfeel in baked goods, beverages, and tabletop blends
✓Often blended with high-intensity sweeteners (stevia, monk fruit) to mask aftertaste and add volume

Dosing & Compounds

Typical Dose
FDA: Generally Recognized As Safe (GRAS) since 2001, no numeric limit. JECFA (2000): ADI "not specified" (the safest category). EFSA (2023 re-evaluation): established a numeric ADI of 0.5 g/kg body weight/day, derived from the human NOAEL for diarrhea — EFSA noted that high consumers, especially children and adolescents, can exceed this. EU labelling: products require "excessive consumption may produce laxative effects."
Active Compounds
E-number E968 (EU); INS 968Found in 'keto'/'sugar-free' products: tabletop sweeteners (Truvia, Swerve, Whole Earth, Splenda Naturals blends), sugar-free chocolate, gum, baked goods, protein bars, and reduced-calorie beveragesFrequently combined with stevia or monk fruit extractAlso occurs naturally in fruits (grapes, melons, pears) and fermented foods (wine, soy sauce, cheese), and is produced endogenously in the body via the pentose phosphate pathway

Safety & Cautions

Documented harm is primarily GI: doses above roughly 0.5 g/kg (or ~50 g acutely) can cause bloating, gas, and diarrhea, though erythritol is far better tolerated than other sugar alcohols because most is absorbed rather than fermented. The notable emerging signal is cardiovascular: Witkowski et al. (Nature Medicine 2023) found that higher fasting plasma erythritol independently predicted 3-year major adverse cardiovascular events across three cohorts (>4,000 patients; adjusted HR ~1.8-2.2, top vs bottom quartile) and showed in vitro and in a small human ingestion study (30 g, n=10) that erythritol enhances platelet aggregation and clot formation. These findings are associational/mechanistic, not from randomized outcome trials; high plasma levels may partly reflect endogenous production in people who already have cardiometabolic disease (reverse causation/confounding), and the FDA and industry have noted these limitations. No carcinogenicity or genotoxicity signal exists. People with a history of clotting events or significant cardiovascular disease may reasonably wish to limit intake pending confirmatory trials; those prone to GI symptoms should moderate dose. Educational only — always check with your doctor or pharmacist before combining Erythritol with any medicine.

Key Studies ★ 11 studies

regulatory assessment EFSA ANS Panel 2023 ✓ Source
Re-evaluation set an ADI of 0.5 g/kg body weight/day based on the NOAEL for diarrhea, and concluded high consumers (notably children/adolescents) can exceed it; retained the laxative-warning requirement.
regulatory commentary FDA evaluation of Witkowski 2023 ✓ Source
FDA's scientific evaluation noted the cohort findings are associational and cannot establish causation given confounding and endogenous erythritol production, and did not change erythritol's regulatory status.
RCT Mahdi/Hazen 2024 (ATVB) ✓ PubMed
Prospective interventional trial in healthy volunteers: ingestion of 30 g erythritol (but not 30 g glucose) acutely and significantly increased stimulus-dependent platelet aggregation and thrombosis potential.
regulatory determination JECFA 2000 / FDA GRAS 2001 ✓ Full text
JECFA assigned an ADI 'not specified' and the FDA accepted GRAS status for erythritol as a sweetener and flavor enhancer, reflecting low toxicity in animal and human studies.
review Mazi & Stanhope 2023 (review) ✓ Full text
Narrative review concluded erythritol has minimal acute metabolic/glycemic effects but flagged the Witkowski cardiovascular findings and endogenous-production confounding as key unresolved questions requiring controlled long-term trials.
cohort + mechanistic Witkowski et al. 2023 ✓ PubMed
Across US and EU cohorts (n=1,157 discovery; n=2,149 and n=833 validation), highest vs lowest plasma erythritol quartile carried adjusted HRs of 1.80 and 2.21 for 3-year MACE; erythritol enhanced platelet reactivity and thrombosis in vitro and in mice.
Observational ARIC Study 2025 (JACC: Advances) ✓ Full text
In 4,006 older adults (median 8.4-yr follow-up), erythritol was associated with total mortality (HR 1.18, 95% CI 1.10-1.26) and its metabolite erythronate with incident CHD (HR 1.32, 1.06-1.63) and ischemic stroke (HR 1.37, 1.05-1.78).
Observational Sylvetsky/Seidelmann 2025 (J Appl Physiol) ✓ PubMed
In human cerebral microvascular endothelial cells, a 30 g-beverage-equivalent erythritol dose (6 mM) reduced nitric oxide production, raised oxidative stress and endothelin-1, and impaired t-PA fibrinolytic response, supporting a cerebrovascular/stroke-risk mechanism.
Observational MR Analysis 2025 (Medicine) ✓ Full text
Two-sample Mendelian randomization found genetically predicted erythritol associated with increased risk of coronary heart disease, ischemic stroke, and venous thromboembolism, supporting a potential causal contribution.
prospective interventional (human) Witkowski et al. 2024 (ATVB) ✓ Full text
In healthy volunteers, ingesting 30 g erythritol (n=10) — but not 30 g glucose — raised plasma erythritol >1,000-fold and acutely enhanced stimulus-dependent platelet aggregation and granule release.
pharmacokinetic study Bornet et al. 1996 ✓ PubMed
Plasma/urine kinetics in healthy humans showed erythritol is rapidly absorbed, not metabolized, and ~80-90% recovered unchanged in urine within 24-48 h, explaining its near-zero caloric and glycemic profile.
11 sources cited · 11 verified Search all studies on PubMed ↗

Common questions about Erythritol

What is Erythritol used for?

Erythritol is most often taken for Zero/near-zero calorie sweetness (0-0.2 kcal/g, ~60-70% as sweet as sugar), No meaningful glycemic or insulin impact (glycemic index ~0) — suitable for diabetics and keto/low-carb diets, ~90% absorbed in small intestine and excreted unchanged, so far better GI tolerance than other polyols (sorbitol, maltitol), Non-cariogenic — not fermented by oral bacteria, does not promote tooth decay. Zero-calorie sugar alcohol under fresh cardiovascular scrutiny

Does Erythritol work — what does the evidence say?

Mixed evidence. Conflicting results across studies; benefit uncertain. Erythritol (E968) is a four-carbon sugar alcohol (polyol) used as a bulk, zero-calorie sweetener with about 60-70% the sweetness of sucrose. It is FDA GRAS (since 2001) and was given a JECFA ADI of "not specified" (2000); in a 2023 re-evaluation EFSA set an ADI of 0.5 g/kg body weight/day based solely on its laxative threshold. Unlike most polyols it is ~90% absorbed in the small intestine, not metabolized, and excreted unchanged in urine, giving it minimal glycemic, insulin, and GI impact at moderate doses. The weight of human evidence is reassuring for short-term metabolic safety but is now mixed because recent observational and mechanistic studies (Witkowski 2023-2024) link elevated circulating erythritol and acute ingestion to enhanced platelet reactivity and incident cardiovascular events — an unconfirmed signal under active study, complicated by the fact that erythritol is also produced endogenously.

What is the typical dose of Erythritol?

FDA: Generally Recognized As Safe (GRAS) since 2001, no numeric limit. JECFA (2000): ADI "not specified" (the safest category). EFSA (2023 re-evaluation): established a numeric ADI of 0.5 g/kg body weight/day, derived from the human NOAEL for diarrhea — EFSA noted that high consumers, especially children and adolescents, can exceed this. EU labelling: products require "excessive consumption may produce laxative effects."

Is Erythritol safe? Any cautions or side effects?

Documented harm is primarily GI: doses above roughly 0.5 g/kg (or ~50 g acutely) can cause bloating, gas, and diarrhea, though erythritol is far better tolerated than other sugar alcohols because most is absorbed rather than fermented. The notable emerging signal is cardiovascular: Witkowski et al. (Nature Medicine 2023) found that higher fasting plasma erythritol independently predicted 3-year major adverse cardiovascular events across three cohorts (>4,000 patients; adjusted HR ~1.8-2.2, top vs bottom quartile) and showed in vitro and in a small human ingestion study (30 g, n=10) that erythritol enhances platelet aggregation and clot formation. These findings are associational/mechanistic, not from randomized outcome trials; high plasma levels may partly reflect endogenous production in people who already have cardiometabolic disease (reverse causation/confounding), and the FDA and industry have noted these limitations. No carcinogenicity or genotoxicity signal exists. People with a history of clotting events or significant cardiovascular disease may reasonably wish to limit intake pending confirmatory trials; those prone to GI symptoms should moderate dose.

How many studies support Erythritol?

NutriDex cites 11 sources for Erythritol, graded "Mixed".

Cite this page
APA

Peh, D. (2026). Erythritol (E968 · sugar alcohol): Benefits, Dosage, Side Effects & Evidence. NutriDex — The Supplement Research Compendium. Retrieved 26 Jun 2026, from https://nutridex.info/s/erythritol

BibTeX
@misc{nutridex_erythritol,
  author       = {Peh, Daryl},
  title        = {Erythritol (E968 · sugar alcohol): Benefits, Dosage, Side Effects \& Evidence},
  year         = {2026},
  howpublished = {NutriDex --- The Supplement Research Compendium},
  url          = {https://nutridex.info/s/erythritol},
  note         = {Reviewed by Dr Daryl Peh, MBBS Singapore, MMed FM. Accessed 2026-06-26}
}

For medical claims, citing the underlying primary studies linked above is preferred. NutriDex is an educational reference, not medical advice.

← Back to the full dex · All substances